Alembic Pharmaceuticals has announced the incorporation of a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, based in Germany. With a share capital of EUR 25,000, this new entity marks a strategic step to explore business opportunities and enhance the company’s distribution capabilities for its pharmaceutical products within the European region. The subsidiary is currently in its initial setup phase and has yet to commence business operations.
Strategic European Footprint
As part of its international growth strategy, Alembic Pharmaceuticals has established a new entity, Alembic Pharmaceuticals GmbH, in Germany. This expansion is designed to facilitate the promotion, sales, and distribution of the company’s pharmaceutical products across the German market, allowing for better access to local business opportunities.
Capital and Operational Status
The newly formed subsidiary is a wholly owned unit of the parent company. It has been capitalized with EUR 25,000, divided into 25,000 shares valued at EUR 1.00 each. As the entity is newly incorporated, it is currently in its pre-operational phase and has reported a nil turnover to date. The company intends to leverage this presence to strengthen its global reach and streamline its supply chain within the European pharmaceutical sector.
Source: BSE
